OTIC - Otonomy, Inc.
| Previous Close | 2.5100 |
| Open | 2.5000 |
| Bid | 0.0000 x 1200 |
| Ask | 0.0000 x 2200 |
| Day's Range | 2.5000 - 2.5300 |
| 52 Week Range | 1.5000 - 3.9500 |
| Volume | 36,213 |
| Avg. Volume | 38,960 |
| Market Cap | 77.02M |
| Beta (3Y Monthly) | 1.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6630 |
| Earnings Date | Mar 6, 2019 - Mar 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.33 |
- Simply Wall St.•11 days ago
Why Otonomy, Inc. (NASDAQ:OTIC) Is An Attractive Investment To Consider
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I...
- GlobeNewswire•last month
Otonomy to Present at the Raymond James Life Sciences and MedTech Conference
SAN DIEGO, June 12, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of OTIC earnings conference call or presentation 6-May-19 8:30pm GMT
Q1 2019 Otonomy Inc Earnings Call
- Zacks•3 months ago
Otonomy (OTIC) Reports Q1 Loss, Misses Revenue Estimates
Otonomy (OTIC) delivered earnings and revenue surprises of 15.22% and -40.92%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Otonomy: 1Q Earnings Snapshot
The San Diego-based company said it had a loss of 39 cents per share. The biotechnology company posted revenue of $192,000 in the period. In the final minutes of trading on Monday, the company's shares ...
- GlobeNewswire•3 months ago
Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update
OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020OTIPRIO® co-promotion agreement completed with Glenmark TherapeuticsOTIVIDEX™ Phase 3 trial.
- ACCESSWIRE•3 months ago
Otonomy, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 6, 2019 / Otonomy, Inc. (NASDAQ: OTIC ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 6, 2019 at 4:30 PM Eastern Time. ...
- PR Newswire•3 months ago
Glenmark Therapeutics Expands Specialty Portfolio with OTIPRIO® Co-Promotion Agreement in the U.S. with Otonomy for Acute Otitis Externa Indication
MAHWAH, N.J., May 2, 2019 /PRNewswire/ -- Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding SA., today announced a co-promotion agreement with Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. Glenmark Therapeutics is dedicated to developing and commercializing a franchise of branded products for Glenmark Pharmaceuticals and is focused in the areas of respiratory and dermatology. Ryaltris™ (olopatadine hydrochloride [665 mcg] and mometasone furoate [25 mcg]), formerly GSP 301 Nasal Spray, is the company's leading respiratory pipeline asset and currently under review with the U.S. Food and Drug Administration (FDA) as a treatment for seasonal allergic rhinitis in patients 12 years and older.
- GlobeNewswire•3 months ago
Otonomy Announces OTIPRIO® Co-Promotion Agreement with Glenmark Therapeutics for Acute Otitis Externa Indication
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the signing of a co-promotion agreement with Glenmark Therapeutics Inc., USA, a wholly-owned subsidiary of Glenmark Holding SA., which is dedicated to building and commercializing a franchise of branded products for Glenmark Pharmaceuticals focused in the areas of respiratory and dermatology. This agreement provides Glenmark Therapeutics with an exclusive right to promote OTIPRIO (ciprofloxacin otic suspension) to ear, nose and throat (ENT) physician offices in the United States and its territories for the treatment of acute otitis externa (AOE) in patients 6 months of age and older due to Pseudomonas aeruginosa and Staphylococcus aureus.
- GlobeNewswire•3 months ago
Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit
SAN DIEGO, May 01, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- GlobeNewswire•3 months ago
Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2019 as well as provide a corporate update at 4:30 p.m. EDT on May 6, 2019. The live call may be accessed by dialing (877) 305-6769 for domestic callers and (678) 562-4239 for international callers with conference ID code number: 8076448. A live webcast of the call will be available online in the investor relations section of Otonomy’s website at www.otonomy.com and will be archived there for 30 days.
- Simply Wall St.•3 months ago
Do Institutions Own Otonomy, Inc. (NASDAQ:OTIC) Shares?
If you want to know who really controls Otonomy, Inc. (NASDAQ:OTIC), then you'll have to look at the makeup of its share registry. Institutions often own shares in more established companies, while it's not unusual to see insiders...
- GlobeNewswire•3 months ago
Otonomy Initiates Phase 1/2 Clinical Trial of OTO-313 in Tinnitus
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-313, a sustained-exposure formulation of the NMDA receptor antagonist gacyclidine, in patients with tinnitus. The randomized, double-blind, placebo-controlled Phase 1/2 study will include an initial safety cohort followed by an exploratory efficacy study that will enroll approximately 50 patients with subjective tinnitus. "Tinnitus is a common problem affecting millions of people,” said Susan Marenda King, M.D., Neurotologist and Otologist at the Ear Medical Group in San Antonio, and Clinical Professor at the University of Texas Health Science Center.
- Zacks•4 months ago
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
- Zacks•4 months ago
Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.
- Zacks•4 months ago
Will Otonomy Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Otonomy.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of OTIC earnings conference call or presentation 4-Mar-19 9:30pm GMT
Q4 2018 Otonomy Inc Earnings Call
- Simply Wall St.•5 months ago
Those Who Purchased Otonomy Shares Three Years Ago Have A 84% Loss To Show For It
Otonomy, Inc. (NASDAQ:OTIC) shareholders should be happy to see the share price up 18% in the last month. But that is meagre solace in the face of the shocking declineRead More...
- GlobeNewswire•5 months ago
Otonomy to Participate in Two Upcoming Investor Conferences
SAN DIEGO, March 05, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- GlobeNewswire•5 months ago
Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for results in first half 2020 OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019OTO-413 Phase.
- GlobeNewswire•5 months ago
Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update
SAN DIEGO, Feb. 25, 2019 -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced.
- GlobeNewswire•5 months ago
Analysis: Positioning to Benefit within Apache, A. O. Smith, Diamondback Energy, Maiden, Lands' End, and Otonomy — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•5 months ago
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced multiple presentations at the upcoming Association for Research in Otolaryngology (ARO) 42nd Annual MidWinter Meeting, to be held February 9-13, in Baltimore. “Our multiple presentations at ARO demonstrate our broad pipeline in neurotology with data presented in support of our product candidates for Ménière’s disease, tinnitus, hearing loss and otoprotection," said Kathie Bishop, Ph.D., chief scientific officer of Otonomy.
- Simply Wall St.•6 months ago
An Examination Of Otonomy, Inc. (NASDAQ:OTIC)
As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health to Read More...
- GlobeNewswire•7 months ago
Otonomy Provides Corporate and Product Pipeline Update
Otonomy, Inc. (OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an update on its product pipeline and financial guidance. The company expects to have clinical trial results for three programs in 2020 including the previously announced Phase 3 trial of OTIVIDEX in Ménière’s disease in the first half of 2020, Phase 1/2 trial of OTO-313 in tinnitus patients in the first half of 2020, and Phase 1/2 trial of OTO-413 in patients with hearing loss in the second half of 2020. The company finished 2018 with approximately $97 million in cash, cash equivalents and short term investments that includes proceeds from a $15 million term loan from Oxford Finance LLC completed in December 2018.
